Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 1,666

The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.

Biomarkers in Cancer Staging, Prognosis and Treatment Selection

Ludwig, Joseph A., Weinstein, John N. · 2005 · Nature Reviews Cancer

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrc1739

Cites

118 of 118 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 27

  1. Sobin, L. H. TNM: evolution and relation to other prognostic factors. Semin. Surg. Oncol. 21, 3–7 (2003). Historical perspective of the TNM staging guidelines. · doi:10.1002/ssu.10014
  2. American Joint Committee on Cancer & American Cancer Society. AJCC Cancer Staging Handbook: from the AJCC Cancer Staging Manual (eds Greene, F. L. et al.) (Springer, New York, 2002). AJCC guidelines for cancer staging.
  3. McQuade, P. & Knight, L. C. Radiopharmaceuticals for targeting the angiogenesis marker αvβ3 . Q. J. Nucl. Med. 47, 209–220 (2003).
  4. Kuge, Y. et al. Feasibility of 99mTc-annexin V for repetitive detection of apoptotic tumor response to chemotherapy: an experimental study using a rat tumor model. J. Nucl. Med. 45, 309–312 (2004).
  5. Krohn, K. A. Evaluation of alternative approaches for imaging cellular growth. Q. J. Nucl. Med. 45, 174–178 (2001).
  6. Kaneda, H. et al. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. Lung Cancer 46, 247–254 (2004). · DOI
  7. Lenz, H. J. The use and development of germline polymorphisms in clinical oncology. J. Clin. Oncol. 22, 2519–2521 (2004). · doi:10.1200/jco.2004.04.900
  8. Stathopoulou, A. et al. Real-time quantification of CK-19 mrna-positive cells in peripheral blood of breast cancer patients using the lightcycler system. Clin. Cancer Res. 9, 5145–5151 (2003).
  9. Muller, V. & Pantel, K. Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives. Breast Cancer Res. 6, 258–261 (2004). · doi:10.1186/bcr942
  10. Best, C. J. et al. Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis. Diagn. Mol. Pathol. 12, 63–70 (2003). · doi:10.1097/00019606-200306000-00001
  11. Service, R. F. American Chemical Society Meeting. Tiny transistors scout for cancer. Science 300, 242–243 (2003).
  12. Ben-Ari, E. T. Nanoscale quantum dots hold promise for cancer applications. J. Natl Cancer Inst. 95, 502–504 (2003). · doi:10.1093/jnci/95.7.502
  13. Patel, V., Leethanakul, C. & Gutkind, J. S. New approaches to the understanding of the molecular basis of oral cancer. Crit. Rev. Oral Biol. Med. 12, 55–63 (2001). · doi:10.1177/10454411010120010401
  14. Ornstein, D. K. et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21, 2235–2242 (2000). · doi:10.1002/1522-2683(20000601)21:11<2235::aid-elps2235>3.0.co;2-a
  15. Gutman, S. Regulatory issues in tumor marker development. Semin. Oncol. 29, 294–300 (2002). Examines the regulatory environment surrounding biomarker approval by the FDA and CMS. · doi:10.1053/sonc.2002.33140
  16. Taube, S. E. & Freiberg, G. P. Regulatory issues related to marker development. Urol. Oncol. 5, 214–216 (2000). · doi:10.1016/s1078-1439(00)00076-4
  17. Hackett, J. L. & Lesko, L. J. Microarray data — the US FDA, industry and academia. Nature Biotechnol. 21, 742–743 (2003). · doi:10.1038/nbt0703-742
  18. Mendelsohn, A. R. & Brent, R. Postgenomic protein analysis: the next bend in the river. Nature Biotechnol. 16, 520–521 (1998). · doi:10.1038/nbt0698-520
  19. Togashi, K. Ovarian cancer: the clinical role of US, CT, and MRI. Eur. Radiol. 13 (Suppl. 4), L87–L104 (2003). · doi:10.1007/s00330-003-1964-y
  20. Depres-Brummer, P. et al. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer. J. Cancer Res. Clin. Oncol. 121, 419–422 (1995). · doi:10.1007/bf01212949
  21. Duncan, J. L., Price, A. & Rogers, K. The use of CA15.3 as a serum tumour marker in breast carcinoma. Eur. J. Surg. Oncol 17, 16–19 (1991).
  22. Gion, M. et al. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients. Cancer J. 7, 181–190 (2001).
  23. Lee, S. G. et al. Genetic polymorphisms of XRCC1 and risk of gastric cancer. Cancer Lett. 187, 53–60 (2002). · doi:10.1016/s0304-3835(02)00381-6
  24. Hoque, M. O., Lee, C. C., Cairns, P., Schoenberg, M. & Sidransky, D. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res. 63, 2216–2222 (2003).
  25. Mueller, N. Overview: viral agents and cancer. Environ. Health Perspect. 103 (Suppl. 8), 259–261 (1995).
  26. Pellet, C. et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J. Invest. Dermatol. 117, 858–863 (2001). · doi:10.1046/j.0022-202x.2001.01465.x
  27. Weinstein, J. N. Fishing expeditions. Science 282, 628–629 (1998). · doi:10.1126/science.282.5389.627g

Cited by

See all 1,666

Metadata

Authors
Ludwig, J. A., & Weinstein, J. N.
Venue
Nature Reviews Cancer
Published
2005-10-20
Volume
5
Issue
11
Pages
845-856
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
OpenAlex
W2126415088
Cited by
1,666
References
118
FWCI
2.61
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.